Search research articles
Contact Us
Filters
Showing results (121-130 of 149) with videos related to
Page
of 15
Sort By:
British Journal of Cancer
|
January 10, 2008
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
D Balin-Gauthier, J-P Delord, M-J Pillaire, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2005
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
J P Delord, C Allal, M Canal, et al.
Seminars in Oncology
|
April 1, 1989
Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers
M J George, J F Heron, P Kerbrat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2007
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
E Van Cutsem, C Verslype, P Beale, et al.
Cancer Research
|
August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
M de Forni, R Bugat, G G Chabot, et al.
British Journal of Cancer
|
August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups
G Freyer, P Rougier, R Bugat, et al.
Bulletin Du Cancer
|
February 1, 1993
[Intraperitoneal administration of interferon gamma. An efficient adjuvant to the chemotherapy of ovarian cancers. Apropos of an European study of 108 patients]
E Pujade-Lauraine, J P Guastella, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
G G Chabot, D Abigerges, G Catimel, et al.
Clinical Pharmacology and Therapeutics
|
October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokinetics
C Terret, E Erdociain, R Guimbaud, et al.
Cancer Chemotherapy and Pharmacology
|
December 29, 2000
Population pharmacokinetics of topotecan: intraindividual variability in total drug
A Montazeri, M Boucaud, F Lokiec, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 149) with videos related to
Sort By:
Page
of 15
British Journal of Cancer
|
January 10, 2008
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
D Balin-Gauthier, J-P Delord, M-J Pillaire, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2005
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
J P Delord, C Allal, M Canal, et al.
Seminars in Oncology
|
April 1, 1989
Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers
M J George, J F Heron, P Kerbrat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2007
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
E Van Cutsem, C Verslype, P Beale, et al.
Cancer Research
|
August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
M de Forni, R Bugat, G G Chabot, et al.
British Journal of Cancer
|
August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups
G Freyer, P Rougier, R Bugat, et al.
Bulletin Du Cancer
|
February 1, 1993
[Intraperitoneal administration of interferon gamma. An efficient adjuvant to the chemotherapy of ovarian cancers. Apropos of an European study of 108 patients]
E Pujade-Lauraine, J P Guastella, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
G G Chabot, D Abigerges, G Catimel, et al.
Clinical Pharmacology and Therapeutics
|
October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokinetics
C Terret, E Erdociain, R Guimbaud, et al.
Cancer Chemotherapy and Pharmacology
|
December 29, 2000
Population pharmacokinetics of topotecan: intraindividual variability in total drug
A Montazeri, M Boucaud, F Lokiec, et al.
Page
of 15